Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE).

Published

Journal Article

Desirudin, a subcutaneously (SC) administered direct thrombin inhibitor, is indicated for prevention of venous thromboembolic events (VTEs) after total joint replacement surgery. DESIR-ABLE (multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation) was a multicenter, open-label, single-arm study of hospitalized patients requiring VTE protection designed to extend the safety profile for desirudin to include a broad population of perioperative/critically ill patients. The primary end point was major bleeding. A total of 516 patients undergoing major surgery (378, 73%) or who were medically ill with prolonged immobility (138, 27%) were enrolled at 19 centers and received desirudin 15 mg Q12H. Many patients had high-risk features for bleeding and thrombosis such as thrombocytopenia (<100 x 10(9)/mL, n = 50), severe obesity (body mass index >35, n = 145), and renal impairment (creatinine clearance <60 mL/min, n = 292). There were no major bleeds and no VTE-related deaths in this study. The DESIR-ABLE demonstrated the safety of desirudin in critically ill perioperative and medical patients. Trials in specific surgical or medically ill patients are needed to confirm these findings.

Full Text

Duke Authors

Cited Authors

  • Bergese, SD; Minkowitz, HS; Arpino, PA; Sane, DC; Levy, JH

Published Date

  • July 2013

Published In

Volume / Issue

  • 19 / 4

Start / End Page

  • 418 - 423

PubMed ID

  • 22802554

Pubmed Central ID

  • 22802554

Electronic International Standard Serial Number (EISSN)

  • 1938-2723

Digital Object Identifier (DOI)

  • 10.1177/1076029612452779

Language

  • eng

Conference Location

  • United States